Kellogg settles with FTC
This article was originally published in The Tan Sheet
Kellogg Co. settles Federal Trade Commission allegations that it falsely advertised Frosted Mini-Wheats as "clinically shown to improve kids' attentiveness by nearly 20 percent." The commission alleged that the study Kellogg relied on for the claim shows only one in nine children's attentiveness improved by 20 percent or more, according to an April 20 FTC release. The commission also alleged that the study shows children who ate the cereal for breakfast were on average 11 percent more attentive than those who skipped breakfast. This contradicts the company's claim that attentiveness improved 20 percent, the commission says. The settlement prohibits Kellogg from making unsubstantiated claims and misrepresenting study results, but does not impose a fine or consumer redress
You may also be interested in...
The Federal Trade Commission approves a final consent order to resolve allegations Kellogg Company falsely advertised Frosted Mini-Wheats as "clinically shown to improve kids' attentiveness nearly 20 percent." The Commission said data Kellogg relied on to make the claim was self-contradictory and did not support the statement (1"The Tan Sheet" April 27, 2009)
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.